Drug firm, Lupin, on Friday said Indian business is still under dark clouds due to tough regulatory environment.
In an interview to CNBC-TV18, Ramesh Swaminathan, chief financial officer and executive director, said the third quarter is better for US business compared to last two quarters as price pressure is easing in the American market.
Swaminathan said there is a price stability in the US market except some increase seen in some generics.
Further, he said top American pharma companies are shedding part of their portfolio in the benefit of Indian firms.
Speaking about his outlook for India business in the short-term, Swaminathan said it's pretty good, adding that company is working with US Food and Drug Administration (FDA) on remedy for Pithampur and Goa facilities.